First evaluation in Argentina of the GenoType® MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from clinical isolates and specimens;Primera evaluación en Argentina de GenoType® MTBDRplus para la detección de Mycobacterium tuberculosis multidrogo-resistente desde aislamientos y especímenes clínicos

Revista Argentina de Microbiologia

Volumn 44, Issue 4, 2012, Pages 283-289

  Imperiale, Belén R ^a   Zumárraga, Martín J ^b   Weltman, Gabriela ^c   Zudiker, Roxana ^c   Cataldi, Ángel A ^b   Morcillo, Nora S ^a  

^a Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^c not available   (Argentina)

Author keywords

GenoType MTBDRplus; Molecular detection; Multidrug resistant tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; SPOLIGOTYPING;

EID: 84872516702     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI. Use of the GenoType® MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clin Pathol 2010; 10: 5.
2. BD BACTEC MGIT 960 SIRE kits for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Becton Dickinson. Sparks, MD, USA: Becton Dickinson, 2005.
3. Bravo LT, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, Gordon SM, Hall GS, Shrestha NK. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid and fuoroquinolones. J Clin Microbiol 2009; 47: 3985-3990.
4. Cardoso RF, Cooksey RC, Morlock GP, Barco P, Cecon L, Forestiero F, Leite CQ, Sato DN, Shikama ML, Mamizuka EM, Hirata RD, Hirata MH. Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis obtained in Brazil. Antimicrob Agents Chemother 2004; 48: 3373-3381.
5. Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. Mutations prevalent among rifampin- and isoniazid- resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 2006; 44: 2333-2337.
6. Coronel J, Roper M, Mitchell S, Castillo E, Gamarra N, Drobniewski F, Luna G, Mendoza A, Moore DA. MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus. Int J Tuberc Lung Dis 2010; 14: 1475-1480.
7. Hain Lifescience GmBH. GenoType®MTBDRplus kit manual, p. 23.
8. Hanna B, Ebrahimzadeh A, Elliott B, Morgan M, Novak SM, Rusch-Gerdes S, Acio M, Dunbar DF, Holmes TM, Rexer CH, Savthyakumar C, Vannier AM. Multicenter evaluation of the Bactec MGIT 960 system for the recovery of mycobacteria. J Clin Microbiol 1999; 37: 748-752.
9. Heifets LB. Conventional methods for antimicrobial susceptibility testing of M. tuberculosis. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. London, UK, Kluwer Academic Publishers, 2001, p. 135-136.
10. Heym B, Saint-Joanis B, Cole ST. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1999; 74: 267-271.
11. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBD R plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 8: 2635-2640.
12. Huyen M, Tiemersma E, Lan N, Cobelens F, Dung N, Sy D, Buu T, Kremer K, Hang P, Caws M, O ́Brien R, van Soolingen D. Validation of the GenoType® MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010; 10: 149.
13. Imperiale BR, Cataldi AA, Morcillo NS. Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specifc polymerase chain reaction. Int J Tuberc Lung Dis 2011; 15: 496-501.
14. Instituto Nacional de Enfermedades Respiratorias Emilio Coni. Situación de la tuberculosis en la Argentina. Ministerio de Salud y Medio Ambiente de la Nación. Septiembre 2011.
15. Kent PT, Kubica GP. Public Health microbiology. A guide for a level III laboratory. Centers for Disease Control, Atlanta GA, 1985.
16. Mattelli A, Migliori GB, Cirillo D, Centis R, Girardi E, Raviglione M. Multidrug-resistant and extensively drug- resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007; 5: 857-871.
17. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is"science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
18. Mokrousov I, Bhanu NV, Suffys PN, Kadival GV, Yap SF, Cho SN, Jordaan AM, Narvskava O, Singh UB, Gomes HM, Lee H, Kulkami SP, Lim KC, Khan BK, van Soolingen D, Victor TC, Schouls LM. Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J Microbiol Methods 2004; 57: 323-335.
19. TM and the colorimetric based method for tuberculosis drug susceptibility testing. Int J Tuberc Lung Dis 2010; 14: 1169-1175.
20. Morcillo N, Imperiale B, Palomino JC. New simple decontamination method improves microscopic detection and culture of mycobacteria in clinical practice. J Infect Drug Resist 2008; 1: 21-26. www.ncbi.nlm.nih. gov/pmc/articles/PMC3108717/?tool=pubmed.
21. Morcillo N, Zumárraga M, Alito, Dolmann A, Schouls L, Cataldi A, Kremer K, van Soolingen D. A low cost, home- made, reverse-line blot hybridization assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2002; 6: 959-965.
22. Nikolayevskyy V, Balabanova Y, Simak T, Malamanova N, Fedorin I, Drobniewski F. Performance of the GenoType MTBDRplus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 2009; 9: 2.
23. Programa de Control de Tuberculosis de la Provincia de Buenos Aires. Informe Epidemiológico Año 2010. Ministerio de Salud, La Plata. Agosto de 2012.
24. Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra Z, Zignol M, van Leth F, Egwaga SM, van Deun A. Evaluation of the GenoType® MTBDRplus assay as a tool for drug resistance surveys. Int J Tuberc Lung Dis 2011; 15: 959-965.
25. Selvey S, Thompson EW, Matthaei K, Lea RA, Irving MG, Griffths LR. β-actin unsuitable internal control for RT- PCR. Mol Cell Probes 2001; 15: 307-311.
26. Servicio Micobacterias. Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Carlos G. Malbran", Argentina. XL Reunión Nacional Anual del Consejo Confederal de Tuberculosis. Buenos Aires, 24 y 25 de noviembre de 2010.
27. van Embden JD, van Gorkom T, Kremer K, Cansen R, van der Zeijst BA, Schouls LM. Genetic variation and evolutionary origin of the direct repeat locus of Mycobacterium tuberculosis complex bacteria. J Bacteriol 2000; 182: 2393-2401.
28. Vijdea R, Stegger M, Sosnovskaja A, Andersen AB, Thomsen VØ, Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isonia zid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008; 27: 1079-1086.
29. WHO. Anti-tuberculosis drug resistance in the world. Fourth global report. 2008. WHO/HTM/TB/2008.394.
30. WHO. Molecular line probes assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. http://www.who.int/tb/features_archive/policy_statement.pdf. June 2008.
31. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response, 2010. WHO/HTM/TB/2010.3. ted May 2011.
32. WHO/IUATLD. Report 3, Geneva. WHO, 2004, p. 146-147.